Zorginstituut Nederland’s Lecanemab Healt...

By HEOR Staff Writer

February 18, 2026

Dutch Health Insurance Rejects Lecanemab Coverage Zorginstituut Nederland's advisory letter dated 13 February 2026 recommends against including lecanemab (Leqembi®) in the Dutch basi...
European Commission Approves Enhanced Wegovy Obesity Treatment Dose
Revised MenACWY Vaccination Strategy for Adolescents in Germany
Genotype ECG Prediction
Glofitamab Cost-Effectiveness: Conditional Reimbursement Insights for DLBCL T...
NICE Endorses Pegzilarginase for Treating Arginase Deficiency
Transformative PBM Reform Legislation Signed into Law
Advancing Cancer Screening in Slovenia: A Pathway to Equitable Care
Late-Breaking Data on Bladder Cancer Treatments from KEYNOTE-B15 Trial
Disrupting Prescription Drug Pricing: Mark Cuban’s Cost-Plus Vision
Robotic Surgery Portugal: A Landmark Achievement at ULS Viseu Dão-Lafões
Pharmaceutical Tender Investigation Sparks Regulatory Scrutiny in South Africa
Strategic Vision and Infarmed 2026 Priorities for Regulatory Reform